Jun 23, 2025, 07:16
TOP Biotechs at ASCO: Kate Dilligan on Scalp Cooling Innovation and Insurance Access
In this episode of TOP Biotechs at ASCO, Kate Diligan, Founder and CEO of Cooler Heads Care, shares how the company is making scalp cooling more affordable, accessible, and clinically validated for cancer patients undergoing chemotherapy.
- Cooler Heads offers the only U.S.-based, FDA-cleared portable scalp cooling system, enabling infusion centers to provide effective scalp cooling profitably.
- Scalp cooling helps patients with solid tumors reduce chemotherapy-induced alopecia, supporting privacy and quality of life—far beyond cosmetic benefits.
- New clinical data shows significant improvements in patient outcomes and emotional well-being with scalp cooling.
- A key regulatory milestone: Starting January 2026, Medicare will reclassify scalp cooling from Category 3 to Category 1 codes, paving the way for broad insurance reimbursement.
- Cooler Heads is actively working with partners to address financial toxicity and expand access to scalp cooling for all eligible patients.
A compelling look at how patient-centered innovation can transform cancer care.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Jun 23, 2025, 07:59
Jun 23, 2025, 07:42
Jun 23, 2025, 07:30